BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37317562)

  • 1. Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy.
    Kroh F; von Knebel Doeberitz N; Breitling J; Maksimovic S; König L; Adeberg S; Scherer M; Unterberg A; Bendszus M; Wick W; Bachert P; Debus J; Ladd ME; Schlemmer HP; Korzowski A; Goerke S; Paech D
    Magn Reson Med; 2023 Oct; 90(4):1569-1581. PubMed ID: 37317562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEST imaging of the APT and ssMT predict the overall survival of patients with glioma at the first follow-up after completion of radiotherapy at 3T.
    von Knebel Doeberitz N; Kroh F; Breitling J; König L; Maksimovic S; Graß S; Adeberg S; Scherer M; Unterberg A; Bendszus M; Wick W; Bachert P; Debus J; Ladd ME; Schlemmer HP; Korzowski A; Goerke S; Paech D
    Radiother Oncol; 2023 Jul; 184():109694. PubMed ID: 37150450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.
    Paech D; Dreher C; Regnery S; Meissner JE; Goerke S; Windschuh J; Oberhollenzer J; Schultheiss M; Deike-Hofmann K; Bickelhaupt S; Radbruch A; Zaiss M; Unterberg A; Wick W; Bendszus M; Bachert P; Ladd ME; Schlemmer HP
    Eur Radiol; 2019 Sep; 29(9):4957-4967. PubMed ID: 30809720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Surgical Depositions of Blood Products Are No Major Confounder for the Diagnostic and Prognostic Performance of CEST MRI in Patients with Glioma.
    von Knebel Doeberitz N; Kroh F; König L; Boyd PS; Graß S; Bauspieß C; Scherer M; Unterberg A; Bendszus M; Wick W; Bachert P; Debus J; Ladd ME; Schlemmer HP; Goerke S; Korzowski A; Paech D
    Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of quantitative metrics in chemical exchange saturation transfer imaging for grading gliomas in adults.
    Liu R; Wang X; Zhao Z; Wen Q; Liu T; Wu D; Wen Z; Zhang Y
    Magn Reson Imaging; 2023 Feb; 96():50-59. PubMed ID: 36403863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D APT and NOE CEST-MRI of healthy volunteers and patients with non-enhancing glioma at 3 T.
    Wu Y; Wood TC; Arzanforoosh F; Hernandez-Tamames JA; Barker GJ; Smits M; Warnert EAH
    MAGMA; 2022 Feb; 35(1):63-73. PubMed ID: 34994858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T.
    Meissner JE; Korzowski A; Regnery S; Goerke S; Breitling J; Floca RO; Debus J; Schlemmer HP; Ladd ME; Bachert P; Adeberg S; Paech D
    J Magn Reson Imaging; 2019 Oct; 50(4):1268-1277. PubMed ID: 30864193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct radiofrequency saturation corrected amide proton transfer tumor MRI at 3T.
    Wu Y; Chen Y; Zhao Y; Yang S; Zhao J; Zhou J; Chen Z; Sun PZ; Zheng H
    Magn Reson Med; 2019 Apr; 81(4):2710-2719. PubMed ID: 30390326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
    Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A
    Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Differentiation of Low-Grade and High-Grade Gliomas and Detection of Tumor Proliferation Using APT Contrast Fitted from Z-Spectrum.
    Zhang J; Zhu W; Tain R; Zhou XJ; Cai K
    Mol Imaging Biol; 2018 Aug; 20(4):623-631. PubMed ID: 29313159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amide proton transfer imaging of glioblastoma, neuroblastoma, and breast cancer cells on a 11.7 T magnetic resonance imaging system.
    Tanoue M; Saito S; Takahashi Y; Araki R; Hashido T; Kioka H; Sakata Y; Yoshioka Y
    Magn Reson Imaging; 2019 Oct; 62():181-190. PubMed ID: 31302222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models.
    Guo H; Liu J; Hu J; Zhang H; Zhao W; Gao M; Zhang Y; Yang G; Cui Y
    J Magn Reson Imaging; 2022 Dec; 56(6):1834-1844. PubMed ID: 35488516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amide proton transfer (APT) and magnetization transfer (MT) in predicting short-term therapeutic outcome in nasopharyngeal carcinoma after chemoradiotherapy: a feasibility study of three-dimensional chemical exchange saturation transfer (CEST) MRI.
    Liu W; Wang X; Xie S; Liu WV; Masokano IB; Bai Y; Chen J; Zhong L; Luo Y; Zhou G; Li W; Pei Y
    Cancer Imaging; 2023 Sep; 23(1):80. PubMed ID: 37658446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-brain amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging in glioma patients using low-power steady-state pulsed chemical exchange saturation transfer (CEST) imaging at 7T.
    Heo HY; Jones CK; Hua J; Yadav N; Agarwal S; Zhou J; van Zijl PC; Pillai JJ
    J Magn Reson Imaging; 2016 Jul; 44(1):41-50. PubMed ID: 26663561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semi-solid magnetization transfer reference (EMR) signals: Application to a rat glioma model at 4.7 Tesla.
    Heo HY; Zhang Y; Lee DH; Hong X; Zhou J
    Magn Reson Med; 2016 Jan; 75(1):137-49. PubMed ID: 25753614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generalization of quasi-steady-state reconstruction to CEST MRI with two-tiered RF saturation and gradient-echo readout-Synergistic nuclear Overhauser enhancement contribution to brain tumor amide proton transfer-weighted MRI.
    Sun PZ
    Magn Reson Med; 2023 May; 89(5):2014-2023. PubMed ID: 36579767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas.
    Ma B; Blakeley JO; Hong X; Zhang H; Jiang S; Blair L; Zhang Y; Heo HY; Zhang M; van Zijl PC; Zhou J
    J Magn Reson Imaging; 2016 Aug; 44(2):456-62. PubMed ID: 26788865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer-weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study.
    Zhang S; Rauch GM; Adrada BE; Boge M; Mohamed RMM; Abdelhafez AH; Son JB; Sun J; Elshafeey NA; White JB; Musall BC; Miyoshi M; Wang X; Kotrotsou A; Wei P; Hwang KP; Ma J; Pagel MD
    Radiol Imaging Cancer; 2021 Sep; 3(5):e200155. PubMed ID: 34477453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular MRI differentiation between primary central nervous system lymphomas and high-grade gliomas using endogenous protein-based amide proton transfer MR imaging at 3 Tesla.
    Jiang S; Yu H; Wang X; Lu S; Li Y; Feng L; Zhang Y; Heo HY; Lee DH; Zhou J; Wen Z
    Eur Radiol; 2016 Jan; 26(1):64-71. PubMed ID: 25925361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of APT-weighted CEST-MRI at 3T in healthy brain and tumor across sessions and scanners.
    Wu Y; Wood TC; Derks SHAE; Pruis IJ; van der Voort S; van Zanten SEMV; Smits M; Warnert EAH
    Sci Rep; 2023 Oct; 13(1):18115. PubMed ID: 37872418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.